On June 5, Cigna Group rose 3.01% in regular trading, trading at $289.13/share, with trading volume of $127 million.

On the news front, Cigna announced it will stop covering GLP-1 weight loss medications — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound — in its employee health plan effective July 1. The market interpreted this move as a positive cost control signal.

The company stated that the decision was made as drug supply has increased and new alternatives have emerged, though coverage for Type 2 diabetes medications remains unaffected. As of last year-end, Cigna employed approximately 67,700 workers, with 88% based in the United States. The discontinuation of GLP-1 reimbursement is expected to significantly reduce employee medical plan expenditures, providing positive support to the company's profit margins. This announcement follows a broader trend among insurers reassessing coverage of costly GLP-1 drugs amid rising utilization rates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)